Back to top

Stifel Nicolaus Initiates a Buy Rating on Gyre Therapeutics (GYRE)

Gyre Therapeutics (GYRE – Research Report) received a Buy rating and a $28.00 price target from Stifel Nicolaus analyst Stephen Willey today. The c...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Gyre Therapeutics, Inc. (GYRE)